Navigation Links
Scorecard to help in diabetic risk assessment of the Indian Population

A new scorecard to enable easy identification of diabetics has been developed as a joint venture by researchers in India, Britain and Australia. . This venture has been materialized following the initiative of the International // Diabetes Federation, and the WHO centre for diabetes and the M.V. Hospital for Diabetes.

The Diabetes Research Centre developed the Indian Diabetes Risk Score in collaboration with Britain's University of Cambridge and the University of Sydney, Australia. Similar scorecards were earlier developed for white European populations in Britain and Denmark.

According to the World Health Organization, India is expected to have 79.4-million diabetes-affected people by 2030. Indian population has been the main target for the new scoreboard risk assessment.

The development has been made possible after the sustained efforts and success of the validation protocols. Initially, 5,000 validation trials were conducted in the southern cities of Chennai, Hyderabad and Bangalore. A separate validation trial was done for Chennai.

The scorecard was developed after trails on 10,000 people. After a first score was developed, this was further validated with another 5,000 trials in Mumbai, New Delhi and Kolkata.

A score of 42 was given against age, body mass, waist girth, family history of diabetes, lifestyle and no physical activity. People over 59 years accumulated 19 points and those over 30 got 10 points.

"Anyone who scores over 21 points is in the category of risk from undetected diabetes," according to Dr.Ramachandran, who has been instrumental behind the scoreboard development.

The scoreboard attracts adherents by its simplicity, ability to be tested and interpreted by paramedics even at remote centres. It also eliminates the need for unnecessary testing. Following introduction, the scoreboard is expected to rock the Indian health market.

Source: Indo-Asian News Servic
'"/>




Page: 1 2

Related medicine news :

1. Scorecard to help in diabetic risk assessment of the Indian Population
2. Gastrointestinal ills more common in diabetics
3. Pollution- hazardous for diabetics
4. New treatment for diabetics
5. Breast screening among diabetic women
6. Needle free future for diabetics
7. Care for footwear not required diabetic patients
8. Nightlights could ward diabetic blindness
9. Gene variant foretells diabetic neuropathy
10. Protein in diabetic neuropathy treatment
11. New target for antidiabetic agents identified
Post Your Comments:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3NASA Research Reveals Major Insight Into Evolution of Life on Earth 4870 1NASA Research Reveals Major Insight Into Evolution of Life on Earth 4870 2The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 1The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 2The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 3The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 4Patch Shots May Someday Replace Injections 54893 1Patch Shots May Someday Replace Injections 54893 2
Other Medicine Technology:New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 2SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 3SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 4SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 5SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 7